RenovoRx, Inc. Profile Avatar - Palmy Investing

RenovoRx, Inc.

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath …

Biotechnology
US, Los Altos [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of RNXT's Analysis
CIK: 1574094 CUSIP: 75989R107 ISIN: US75989R1077 LEI: - UEI: -
Secondary Listings
RNXT has no secondary listings inside our databases.